10-Q: Progyny Q3 2025 Revenue Jumps 9%, Net Income Up 33%

Progyny, Inc. reported strong third-quarter 2025 financial results with a 9% revenue increase and a 33% rise in net income, driven by growth in fertility benefits and Progyny Rx solutions.

Summary

• Revenue for the three months ended September 30, 2025, increased by 9% to $313,346 thousand, up from $286,625 thousand in the prior year period.
• Net income for the three months ended September 30, 2025, rose by 33% to $13,864 thousand, compared to $10,421 thousand in the prior year period.
• Diluted earnings per share for the third quarter of 2025 was $0.15, an increase from $0.11 in the third quarter of 2024.
• Gross profit for the three months ended September 30, 2025, increased by 23% to $72,835 thousand, with gross margin improving by 250 basis points to 23.2%.
• For the nine months ended September 30, 2025, revenue grew 12% to $970,258 thousand, and net income increased 5% to $46,035 thousand.
• The company served 553 clients and approximately 6.7 million members as of September 30, 2025.
• A new share repurchase program of up to $200 million was authorized by the Board of Directors in November 2025.
• A $200 million revolving credit facility was established on July 1, 2025, with no amounts drawn as of the filing date.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and net income growth, coupled with improved gross margins and operational efficiencies. Strategic acquisitions and a new credit facility enhance future growth and liquidity. The authorization of a new share repurchase program indicates confidence in future cash flows. However, the loss of a major client and a decrease in net interest income present some challenges, and the highly regulated industry environment poses ongoing risks.

Positives

• Strong revenue growth of 9% for the three months ended September 30, 2025, and 12% for the nine months ended September 30, 2025, driven by both fertility benefits and Progyny Rx solutions.
• Significant net income increase of 33% for the three months ended September 30, 2025, and 5% for the nine months ended September 30, 2025.
• Improved gross margin by 250 basis points in the third quarter of 2025 (to 23.2%) and 160 basis points for the nine months ended September 30, 2025 (to 23.5%), reflecting ongoing efficiencies in care management services.
• Substantial increase in income from operations by 73% in the third quarter of 2025 and 36% for the nine months ended September 30, 2025.
• Adjusted EBITDA increased by 18% in the third quarter of 2025 to $54,968 thousand and by 13% for the nine months ended September 30, 2025, to $170,704 thousand.
• Growth in client base to 553 and covered lives to approximately 6.7 million as of September 30, 2025.
• High Net Promoter Scores (NPS) of +79 for fertility benefits and +84 for Progyny Rx as of December 31, 2024, indicating strong member satisfaction.
• Demonstrated superior clinical outcomes compared to national averages, including a 46.7% live birth rate per attempted retrieval (vs. 34.9% national) and a 2.1% IVF multiples rate (vs. 5.5% national) as of December 31, 2023.
• Strong liquidity position with $133,982 thousand in cash and cash equivalents and $211,225 thousand in marketable securities as of September 30, 2025.
• Established a new $200 million revolving credit facility on July 1, 2025, enhancing financial flexibility, with no amounts drawn as of the filing date.
• Authorization of a new $200 million share repurchase program in November 2025, signaling confidence in future cash flows and commitment to shareholder returns.
• Successful acquisitions of Benefit Bump LLC (January 2025) and Apryl GmbH (June 2024), expanding offerings in parental leave and global fertility benefits.

Negatives

• Interest and other income, net, decreased significantly by 56% in the third quarter of 2025 and 46% for the nine months ended September 30, 2025, primarily due to decreased investment income and increased interest expense.
• Net cash used in investing activities increased to $167,269 thousand for the nine months ended September 30, 2025, compared to $120,802 thousand provided in the prior year, mainly due to higher purchases of marketable securities and lower sales.
• A large client, which accounted for 12% of total revenue for the nine months ended September 30, 2024, terminated its services agreement effective January 1, 2025.
• The utilization rate for all members slightly decreased to 1.06% for the nine months ended September 30, 2025, from 1.10% in the prior year.
• Bad debt expense increased by $1.2 million in the third quarter of 2025 and $2.6 million for the nine months ended September 30, 2025, driven by revenue growth.

Risks

• Failure to meet publicly announced guidance or other expectations about business and future results of operations, which could cause stock price to decline.
• Operating in a highly competitive market, with potential for new entrants and more established competitors, could harm business, financial condition, and results of operations.
• Unfavorable conditions in the global economy or the industry, including recessionary environments, inflation, interest rate fluctuations, and geopolitical conflicts, could limit business growth and negatively affect results.
• Dependence on the ability to retain existing clients and increase the adoption of services within the client base; failure to do so would harm the business.
• Largest clients account for a significant portion of revenue, and a significant number of clients are in the technology industry, making the business vulnerable to client loss, pricing changes, or industry shifts.
• Inability to attract new clients would adversely affect business, financial condition, and results of operations.
• A significant change in the utilization of fertility solutions, including consumption rate or mix, could have an adverse effect on the business.
• Acquisitions, strategic investments, or partnerships could be difficult to identify, pose integration challenges, divert management attention, disrupt business, dilute stockholder value, and adversely affect results.
• Limited operating history with the current platform of solutions makes it difficult to predict future results of operations.
• The health benefits industry may be subject to negative publicity, which could adversely affect the business.
• Information technology systems, or those of third parties (provider clinics, specialty pharmacies, vendors), lagging, failing, or suffering cybersecurity breaches could lead to service disruption or loss/disclosure of confidential information.
• Dependence on the ability to maintain the Center of Excellence network of high-quality fertility specialists and other healthcare providers; failure to do so would limit future growth.
• Growth depends in part on the success of strategic relationships with, and monitoring of, third parties, including channel partners, vendors, and insurance carriers.
• Failure to maintain an efficient pharmacy distribution network or disruptions to the network of specialty pharmacies or their supply chains could harm the business.
• Operating in a highly regulated industry, requiring compliance with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact.
• Exposure to credit risk from members for co-payments, co-insurance, and deductibles.
• Business with government entities is subject to a number of challenges and risks, including competitive bidding, changing requirements, and budgetary constraints.
• Failure to enforce intellectual property rights could impair the ability to protect proprietary technology and brand.
• Potential inability to utilize a portion of net operating loss carryforwards due to ownership changes.
• Changes in the effective tax rate or tax liabilities may have an adverse effect on results of operations.
• Certain U.S. state tax authorities may assert state nexus and seek to impose state and local taxes.
• Reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States or if estimates/judgments relating to critical accounting policies prove incorrect.
• Stock price may experience volatility, and the value of common stock may decline due to various factors.
• An active trading market for common stock may not be sustained.
• Fluctuations in financial results make it difficult to project future results, and failure to meet expectations could cause stock price to decline.
• Future sales of common stock in the public market, including in connection with financings, acquisitions, or equity incentive plans, could cause the market price to decline and result in dilution.
• If securities or industry analysts do not publish research, or publish unfavorable or inaccurate research, about the business, the market price and trading volume of common stock could decline.
• No intention to pay dividends for the foreseeable future, meaning return on investment depends on stock price appreciation.
• Anti-takeover provisions in charter documents and under Delaware law could make an acquisition more difficult, limit stockholder attempts to replace management, and limit the market price of common stock.
• Designation of Delaware courts as the sole and exclusive forum for certain stockholder actions could discourage lawsuits.
• Subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, with non-compliance leading to criminal or civil liability.
• Changing rules and regulations regarding environmental, social, and governance (ESG) practices and reporting could cause additional costs and risks.

Future Outlook

The company issued guidance for the fourth quarter of 2025 and full year 2025 on November 6, 2025. It expects continued investment in sales, client success teams, new solutions, and technology infrastructure. Management believes existing cash, marketable securities, cash flow from operations, and the new $200 million revolving credit facility will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months and long-term contractual obligations, though additional equity or debt financing may be sought in the future.

Management Comments

• We envision a world where everyone can realize their dreams of family and ideal health.
• Our mission is to empower healthier, supported journeys through transformative fertility, family building and women's health benefits.
• Our purpose-built, data-driven and disruptive platform consistently delivers superior clinical outcomes in a cost-efficient manner while driving exceptional client and member satisfaction.
• We believe there is sufficient positive evidence to conclude that it is more likely than not that substantially all the net deferred tax assets are realizable.
• We believe that our existing cash and cash equivalents, including the proceeds from our marketable securities, cash flow from operations, and the availability of funds under the Facility will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months.

Industry Context

Progyny operates in the highly competitive and evolving health benefits industry, specifically specializing in fertility, family building, and women's health solutions. The company's growth is driven by increasing employer demand for comprehensive benefits to attract and retain talent, as well as societal trends like individuals starting families later and adoption of non-traditional parenthood paths. The industry faces increasing scrutiny and regulation, particularly for Pharmacy Benefit Managers (PBMs), with ongoing legislative and regulatory efforts focused on pricing transparency and rebates. Consolidation among healthcare providers and financial investors acquiring fertility practices are also shaping the competitive landscape. The company's focus on superior clinical outcomes and high member satisfaction positions it favorably amidst these trends, despite the loss of a large client.

Comparison to Industry Standards

• Progyny's in-network provider clinics achieved a 46.7% live birth rate per attempted retrieval for Progyny members, significantly higher than the national average of 34.9% (based on SART 2021 and CDC 2022 data).
• The single embryo transfer rate for Progyny members was 96.6%, substantially above the national average of 78.9%.
• Progyny members experienced a 60.8% pregnancy rate per IVF transfer, compared to the national average of 54.3%.
• The miscarriage rate for Progyny members was 14.4%, lower than the national average of 18.2%.
• The live birth rate per transfer for Progyny members was 52.1%, exceeding the national average of 42.2%.
• The IVF multiples rate for Progyny members was 2.1%, considerably lower than the national average of 5.5%, indicating safer outcomes.
• The company's Net Promoter Scores (NPS) of +79 for fertility benefits and +84 for Progyny Rx as of December 31, 2024, are described as 'industry-leading'.

Corporate Governance

Legal Proceedings

• The company is not aware of any legal proceedings or claims that are believed to have, individually or in the aggregate, a material adverse effect on its financial position or results of operations.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, share repurchase program, and strategic growth, but also risk of dilution from future equity financings and stock price volatility.
• Employees: Benefit from continued investment in personnel (sales, client success, R&D) and access to comprehensive fertility and family building solutions.
• Clients (Employers): Access to superior fertility and family building benefits solutions with high satisfaction and clinical outcomes, but also face the risk of increased costs if utilization exceeds expectations.
• Members (Employees/Dependents): Access to high-quality fertility treatments and pharmacy benefits with strong support from Progyny Care Advocates, leading to healthier pregnancies and superior live birth rates.
• Providers (Fertility Specialists, Pharmacies): Continued partnership within the Center of Excellence network, subject to contractual terms and performance monitoring.
• Creditors: Enhanced security with a new revolving credit facility, but potential for future debt raises.

Next Steps

• Continue to invest significantly in sales and marketing to drive new client acquisition and expand the scope of benefits within the existing client base.
• Introduce new solutions and services to enhance the comprehensive family building offering and technology infrastructure.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on consolidated financial statements and disclosures.
• Potentially seek additional equity or debt financing in the future to support operations and growth.
• Execute the November 2025 share repurchase program of up to $200 million.

Key Dates

Recommendation

Progyny demonstrates robust financial health with strong revenue and net income growth, coupled with expanding gross margins. The company's differentiated service model consistently delivers superior clinical outcomes and high client/member satisfaction, reinforcing its competitive advantage. Strategic acquisitions and a new $200 million share repurchase program signal confidence in future performance and shareholder value creation. While the loss of a large client is a notable headwind, the overall growth trajectory, strong liquidity, and market leadership in a growing sector make it an attractive investment.

Keywords

Fertility Benefits, Family Building, Women's Health, Pharmacy Benefits Management, PBM, Smart Cycles, IVF, Employer Benefits, Healthcare Technology, SEC Filing, 10-Q, Progyny, PGNY, Corporate Wellness, Employee Benefits